RecruitingNCT07247279

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

A Multicenter Non Interventional Single Arm Retrospective-prospective Observational Study in Therapeutic Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis (gMG) in Real Clinical Practice in Russia


Sponsor

AstraZeneca

Enrollment

450 participants

Start Date

Dec 23, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with generalized myasthenia gravis (gmg) and rare diseases. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(7)

Research Site

Kazan', Russia

Research Site

Moscow, Russia

Research Site

Novosibirsk, Russia

Research Site

Rostov-on-Don, Russia

Research Site

Saint Petersburg, Russia

Research Site

Samara, Russia

Research Site

Ufa, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07247279


Related Trials